FOLLOW-UP. Follow-up of patients will be performed by the PI as well as the CRC. The day of the AVF surgery, patients will be interviewed to assess compliance and adverse events. If a patient reports significant side effects, she/he will be asked to discontinue the therapy and the final blood panel will be ordered (LFT, CRP, CPK, and lipids). Otherwise, patients will be reminded to continue with the treatment until their next follow-up appointment with the vascular surgeon 2-3 weeks after operation (5-6 weeks after treatment initiation); when a LFT will be done following the American College of Cardiologists/American Heart Association (ACC/AHA) guidelines for monitoring patients who have begun statin therapy. If any surgical complications arise prior to the final evaluation, these will be recorded and treated accordingly, and the study treatment will be discontinued. The day of the final evaluation (8 weeks after intervention initiation), compliance will be evaluated as well as the AVF status will be assessed by Doppler ultrasound and auscultation; the secondary endpoints will be recorded (AVF diameter and blood flow) and a final lab panel will be drawn as done at baseline. Additional outcomes will include changes in lipid profiles, LFTs, and CRP from baseline; frequency of adverse effects; as well as patient compliance and retention rates in each arm of the study.